Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
about
Harnessing the immune system to improve cancer therapyProducer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsNew Strategies for the Treatment of Solid Tumors with CAR-T CellsRegulation of IL-10 and IL-12 production and function in macrophages and dendritic cellsCAR T cells for solid tumors: armed and ready to go?Genetic engineering with T cell receptorsImmune modulation of the tumor microenvironment for enhancing cancer immunotherapyAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookAdoptive cell therapy for sarcomaCAR-modified T-cell therapy for cancer: an updated review.Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.New insights into IL-12-mediated tumor suppression.The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells.Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cellsmiR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Engager T cells: a new class of antigen-specific T cells that redirect bystander T cellsThe immune microenvironment of myelomaTLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanomaDendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 SignalingAnti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.Genetically modified T-cell therapy for osteosarcomaGenetic modification of human T lymphocytes for the treatment of hematologic malignancies.Identification and characterization of polyclonal αβ-T cells with dendritic cell properties.Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer.New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesThe p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production.Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Collapse of the tumor stroma is triggered by IL-12 induction of Fas.Immunotherapeutic strategies to target prognostic and predictive markers of cancer."Model t" cells: a time-tested vehicle for gene therapyA cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.Design and development of therapies using chimeric antigen receptor-expressing T cellsGUCY2C-targeted cancer immunotherapy: past, present and future.Raising the bar: the curative potential of human cancer immunotherapy.Immunotherapy for the management of advanced melanoma: the next steps.Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
P2860
Q26738698-E8D59BFF-694F-43CB-BF94-0B0BDFE1A6DDQ26741260-BE172893-DAD9-42F3-BCC5-97CA0BB0413AQ26748500-BAE83FDE-5D08-44D4-8492-794BA9053B7AQ26766184-B90326A5-62CD-4AB6-93FA-C544B49B0D30Q26825489-0CD5915E-9DF8-411A-9730-85638FE9284AQ26995677-17EED414-A5EC-4234-B089-F1C7F8875DAEQ27002646-28ED6E20-E55B-4916-AB7F-AC770D265925Q27004178-69A73A1D-D7D1-40ED-985B-1ACC54AD69CCQ27009541-2D41090D-0079-4986-A29C-6F33A989E215Q34044213-7A9CFD6B-403B-4FCD-9AED-C7F809932AC7Q34119602-27E6A6A2-A3D0-47A9-B0B8-56603053C082Q34436897-943B41A5-A8EF-41E5-BF5F-CB6E5B40926FQ34618230-C7E7448E-CBDC-448B-BCF4-B5D963CAA7B6Q34749359-775E3F7B-CD49-4B96-A6DC-8574D507E78BQ34985536-58E6F11A-D0C9-451C-8084-3905D070897CQ35578622-5C6DA8E1-8FAF-4566-9664-73C84A933ED2Q35591391-64CAF00C-6180-479A-9F59-F7AFC3933EB9Q35603152-AA78BEF2-6EE9-487D-92A4-14C4B4FF240BQ35612358-D1DAFE52-0B79-4684-9336-BA94CDEFFA0AQ35613148-361144F4-9250-4B27-ADB2-43031E8E9898Q35674805-C0EE20EE-8163-4574-A046-2933467F0DF4Q35810197-141FE135-75BD-4B20-AA6E-632F40527F7FQ35982211-B46B8E13-058F-4088-A45F-66ECC4542905Q36198232-58A98F67-D46D-46C3-89E8-6D65DD36CE35Q36366557-3F91C406-5A1F-483B-8DEB-A36E4C95ED2AQ36483058-BE728AFC-4FE5-486D-AEAE-47928390A198Q36489567-C53BA1C8-9D02-47AE-AF7D-256A81847B24Q36558375-21FD4082-7DDB-4056-BA2E-AC49535853C8Q36647429-744A3524-1693-4F0B-B310-5CB230FFD395Q36721440-5C882382-3703-48F5-81E1-E984AB55B88DQ36801106-8D75FB2A-3FDC-4C92-A718-92491430D243Q36984473-EF8AD21B-6E5B-46C8-915A-0956C8618973Q37126006-E4A3F678-A555-4A2D-A709-E7EEC460E7A6Q37201423-88A18CC5-E4B6-4205-8C0A-0097A95A9D43Q37362636-82130308-D3ED-42B6-AA56-3D53CADF2247Q37418289-FB6AB5C5-3208-49E2-900C-22801C234F5BQ37950928-38275F73-D184-4880-9E40-18AE7286F660Q37998451-EC15B9F8-7C2D-4DA6-8290-4EB069C35F0EQ38091675-F3C464B1-A7F6-4886-B6E6-B704CF9EC276Q38146713-2DFB3742-B43A-4200-9944-2E977D156AC3
P2860
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Improving adoptive T cell ther ...... sion to the tumor environment.
@ast
Improving adoptive T cell ther ...... sion to the tumor environment.
@en
Improving adoptive T cell ther ...... sion to the tumor environment.
@nl
type
label
Improving adoptive T cell ther ...... sion to the tumor environment.
@ast
Improving adoptive T cell ther ...... sion to the tumor environment.
@en
Improving adoptive T cell ther ...... sion to the tumor environment.
@nl
prefLabel
Improving adoptive T cell ther ...... sion to the tumor environment.
@ast
Improving adoptive T cell ther ...... sion to the tumor environment.
@en
Improving adoptive T cell ther ...... sion to the tumor environment.
@nl
P2093
P2860
P356
P1433
P1476
Improving adoptive T cell ther ...... sion to the tumor environment.
@en
P2093
Ling Zhang
Nicholas P Restifo
Richard A Morgan
Shicheng Yang
Sid P Kerkar
Steven A Rosenberg
Zhili Zheng
P2860
P304
P356
10.1038/MT.2010.313
P577
2011-02-01T00:00:00Z